MEDICAL POLICY

Cardiac: Left Atrial Appendage Devices Closure (Medicare Only)

**Effective Date:** 06/01/2020

<table>
<thead>
<tr>
<th>Medical Officer Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>6/1/2020</td>
</tr>
</tbody>
</table>

See Policy CPT/HCPCS CODE section below for any prior authorization requirements

**SCOPE:**

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

**APPLIES TO:**

Medicare only

**BENEFIT APPLICATION**

**MEDICARE POLICY CRITERIA**

The following Centers for Medicare & Medicaid Service (CMS) guidelines should be utilized for medical necessity coverage determinations. Click the link provided in the table below to access applicable medical necessity criteria. All listed guidelines apply.

<table>
<thead>
<tr>
<th>Service</th>
<th>Medicare Guidelines</th>
</tr>
</thead>
</table>
| Left atrial appendage closure for the treatment of non-valvular atrial fibrillation | • National Coverage Determination (NCD) for Percutaneous Left Atrial Appendage Closure (LAAC) (20.34)³  
• CMS Manual System, Pub 100-04 Medicare Claims Processing, Transmittal 3515, SUBJECT: Percutaneous Left Atrial Appendage Closure (LAAC)² (contains additional coding guidance)  
• Medicare Claims Processing Manual, Chapter 32 – Billing Requirements for Special Services, Section 69³ (scroll to Section 69 in Table of Contents and click on 69 - Qualifying Clinical Trials) |

**POLICY GUIDELINES**

NCD 20.34 allows for coverage of left atrial appendage closure under Coverage with Evidence Development (CED) with certain conditions. The current registries and clinical trials approved by CMS
can be found at the Percutaneous Left Atrial Appendage Closure (LAAC) Coverage with Evidence Development website. See the NCD for additional details. For more information, please see the “Clinical Trials and IDE Studies (Medicare Only)” policy in the Medical Policy Cross References section below.

BILLING GUIDELINES

See Medicare Claims Processing Manual Chapter 32, Section 69.6 - Requirements for Billing Routine Costs of Clinical Trials for additional clinical trial billing instruction.

CPT/HCPCS CODES

The only supply code that is appropriate to bill with the CPT code 33340 is C1760.

<table>
<thead>
<tr>
<th>Medicare Members Only</th>
<th>No Prior Authorization Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>33340</td>
<td>Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transseptal puncture, catheter placement(s), left atrial angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation</td>
</tr>
<tr>
<td>C1760</td>
<td>Closure device, vascular (implantable/insertable)</td>
</tr>
<tr>
<td></td>
<td>The code below is not covered when billed with 33340</td>
</tr>
<tr>
<td>C2628</td>
<td>Catheter, occlusion</td>
</tr>
</tbody>
</table>

DESCRIPTION

Patients with atrial fibrillation (AF), an irregular heartbeat, are at an increased risk of stroke. The left atrial appendage (LAA) is a tubular structure that opens into the left atrium and has been shown to be one potential source for blood clots that can cause strokes. While thinning the blood with anticoagulant medications has been proven to prevent strokes, percutaneous LAA closure (LAAC) has been studied as a non-pharmacologic alternative for patients with AF.

INSTRUCTIONS FOR USE

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days notice of policy changes that are restrictive in nature.
The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

REGULATORY STATUS

Mental Health Parity Statement

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case.

MEDICAL POLICY CROSS REFERENCES

- Clinical Trials and IDE Studies (Medicare Only), MED185

REFERENCES